About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/27/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/27/2021.

Standardized Home Spirometry Method in Normal Population

Clinicaltrials.gov identifier NCT03945500

Recruitment Status Not yet recruiting

First Posted May 10, 2019

Last update posted September 28, 2020

Study Description

Brief summary:

This study was designed to evaluate the feasibility of using a Standardized Home Spirometry (SHS) Method to develop normal range values, to detect a variance (i.e., a value outside of that normal range), to evaluate a variance with a questionnaire, and to download all data in normal volunteers prior to evaluation and use on a larger scale for lung transplant recipients. The Standardized Home Spirometry (SHS) Method consists of a FDA-approved Bluetooth Spirometry unit, FDA approved Bluetooth Pulse Oximeter and an Android-based Tablet which is embedded with an investigational Home Spirometry Mobile Medical Software Application for data and symptom survey collection and transmission over secure WiFi or cellular connectivity in HIPAA compliant fashion (labeled only with a date/time and machine ID stamp) to an associated investigational IT Server Dashboard at the Central Monitoring Institute Server at Washington University in St. Louis.

  • Condition or Disease:Mobile Applications
    Healthy Volunteers
    Feasibility Study
  • Intervention/Treatment: Device: Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter
  • Phase: N/A
Detailed Description

Study Objective: This study was designed to evaluate the feasibility of use of a Standardized Home Spirometry(SHS) Method using a Home Spirometry Monitoring Kit consisting of FDA-approved Blue-tooth Spirometry unit, Blue-tooth pulse oximeter and an Android-based Tablet with an embedded investigational home spirometry mobile medical software application for data and symptom survey collection and transmission over secure WiFi or cellular data transmission portal in HIPAA compliant fashion to an associated investigational IT dashboard application at the Central Monitoring Institute (CMI) Server at Washington University in St. Louis, to develop normal range values, to detect a variance (i.e., a value outside of that normal range), to evaluate a variance with a questionnaire, and to download all data to the CMI in a small pilot of healthy volunteers prior to evaluation and use on a larger scale for lung transplant recipients. The investigational IT application will monitor lung function but do nothing more than collect data. It will adjust monitoring frequency and trigger physician review of home spirometry results at a more frequent interval but will not be directly involved in decisions regarding diagnosis or treatment. Study Type: Non-randomized, single-arm, prospective cohort study Intervention: - The Home Spirometry Monitoring System will consist of: - FDA approved Blue tooth Spirometry unit - FDA approved pulse oximeter - An Android-based tablet with embedded investigational mobile medical software application for symptom survey/data collection and data processing and transmission - WiFi or cellular connectivity to be used for data transmission and communication between an Android Pad and an associated Investigational server dashboard application at the Central Monitoring Institute - Normal Volunteer Monitoring Data is sent in a HIPAA compliant fashion (data with date/time stamp and device ID only) to a Central Monitoring Institute (CMI) server maintained at Washington University in St. Louis - Participants will undergo training to activate and use the Home Spirometry Monitoring System. - Data evaluation by a pulmonologist within CMI: - Trend analysis on a monthly basis and - When a variance is detected with or without potentially associated symptoms. - A monthly summary report - Participants will undergo one Laboratory-based Spirometry Test and perform a test session using the standardized home spirometry method system at baseline. - Participation may last up to one year. Standardized Home Spirometry testing interval at least twice weekly with an initial testing period of greater frequency to enable normal range calibration. Volunteers will require initial in center training with the Standardized home spirometry method & performance of baseline home spirometry method testing and a (baseline) laboratory-based spirometry test. Pre-Surveillance Phase: Daily home spirometry method measurements for 4 to 10 weeks to enable normal range calibration. Surveillance Phase: At least twice weekly home spirometry method measurements for two to ten months of participation. An FEV-1 (Forced Expiratory Volume in one second) variance is defined as an FEV-1 value that is outside the 95% CI (Confidence Interval) of the participant's normal FEV-1 reference range that was determined immediately after enrollment. If an FEV-1 variance is detected by the Android Pad, the IT application automatically requests that the participant complete a symptom survey. This information when used in combination with other data will result in initiation of the following actions: If an FEV-1 variance is categorized as being suspicious for acute medical illness by the CMI (i.e., with clinical symptoms consistent with upper or lower respiratory infection/CHF), the spirometry data and participant survey responses will trigger overview by the CMI laboratory staff and if deemed suspicious for acute medical illness results will be made accessible to the participant's designated health professionals. If critical values or clinical symptoms are obtained consistent with urgent compromise (e.g., evidence of hypoxemia or respiratory distress), the CMI (PFT (Pulmonary Function Testing) Laboratory staff pulmonologist) will make timely attempts to reach the participant or participant's health professionals. In this study, this is expected to be an exceedingly rare occurrence, and most likely would not occur at all. If acute medical illness has been ruled in, participant spirometry surveillance will be reinitiated after an appropriate period of treatment, which will be determined by the participant's managing physician who will notify CMI when the participant has recovered from their acute illness. Variance not suspicious for acute medical illness with no apparent clinical symptoms consistent with infection/CHF: if supplemental questionnaire or clinical data is not consistent with an acute medical illness, the following actions will be taken: Persistence Evaluation: Participants will be directed to obtain daily spirometric measurements along with repeated completion of the questionnaire for a total of 4 consecutive days CMI Pulmonology Review: Consistently low Spirometry values (persistence) will prompt early review of these values along with previous Spirometry history by CMI pulmonology staff. Random Symptom Surveys may also generate (in the absence of a variance) however only Symptom Surveys prompted by Variances will result in further action as described above. During the first two months (approximately) of Surveillance, Volunteers will be directed to intentionally induce variances, symptoms, incomplete connections/testing/survey, etc., in order to fully test and assess the functionality of the Mobile Medical Software neural pathways (IT app and Dashboard server) as directed by the study team. Volunteers will document test on a test log. The FDA issued a non-significant risk (NSR) device study letter on 12/3/2018 for the Home Spirometry Mobile Medical Software.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 20 participants
  • Intervention Model: Single Group Assignment
  • Intervention Model Description: Evaluate the feasibility of using a Standardized Home Spirometry Method and associated investigational Home Spirometry Mobile Medical Software (IT App) and Server "Dashboard" in a healthy volunteer population before beginning a separate full clinical trial in the lung transplant population. Feasibility of using the Standardized Home Spirometry Method and associated Home Spirometry Mobile Medical Software (IT App and Server "Dashboard" to develop normal range values, to detect a value outside of the normal range, to evaluate a value outside of the normal range with a symptom survey and to download all data to a Central Monitoring Institute will be evaluated.
  • Masking: None (Open Label) ()
  • Primary Purpose: Device Feasibility
  • Official Title: Assessment of a Standardized Home Spirometry Method for Frequent Monitoring of Lung Function in a Normal Population
  • Estimated Study Start Date: October 2020
  • Estimated Primary Completion Date: October 2023
  • Estimated Study Completion Date: October 2024
Arms and interventions
Arm Intervention/treatment
Experimental: Standardized Home Spirometry (SHS) Method
The Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet & FDA approved spirometer & pulse oximeter. Participants will be trained with the SHS method & perform an initial home spirometry test session & a laboratory-based spirometry test. Pre-surveillance Phase:Daily SHS Testing for 4 to 10 weeks to enable the Mobile Medical software application to generate volunteer specific normal range calibration. Surveillance Phase: At least twice weekly SHS Testing.If a variance (outside of the participant's normal range) is detected, the participant will be prompted to complete a short symptom survey on the Android Pad. Participants will be directed to intentionally induce variances, symptoms, etc., in order to fully test and assess the functionality of the Mobile Medical software neural pathways as directed by the study team. Volunteers will document this testing on a test log
Device: Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter
Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet, an FDA approved Bluetooth spirometer, an FDA approved pulse oximeter. HIPAA compliant data will be sent to an Investigational IT dashboard maintained at the Central Monitoring Institute Server. Volunteers will train in-center & perform baseline testing with the SHS method along with a baseline laboratory-based spirometry test. Pre-Surveillance Phase: Daily home spirometry method testing for 4 to 10 weeks to enable normal range calibration. Surveillance Phase: At least twice weekly home spirometry method testing for 2-10 months of participation. Volunteers will maintain a test log during study team directed SHS software pathway functionality testing.
Outcome Measures
  • Primary Outcome Measures: 1. Feasibility of using the Standardized Home Spirometry (SHS) Method and associated IT Dashboard Server: Assess Home Spirometry reproducibility during pre-surveillance period. [ Time Frame: Up to 8 weeks ]
    Evaluate daily FEV1 variability between replicate measurements by summarizing between measurement %difference; Evaluate between day variability in highest FEV1 (FEV1 Max) variability by summarizing %Difference from FEV1 Max values and two SD (Standard Deviation) Coefficient of Variation (expected to be less than 30%) between FEV1 measurements during pre-surveillance period.
  • 2. Feasibility of using the Standardized Home Spirometry (SHS) Method and associated IT Dashboard Server: Drift Assessment [ Time Frame: Up to 8 weeks ]
    Evaluate the functionality of the investigational Mobile Medical Software Application and associated IT Server Dashboard for statistically significant drift in relationship between %FEV1 Max or mean FEV1 Max over time and subsequent transition to Surveillance monitoring stage.
  • 3. Feasibility of using the Standardized Home Spirometry (SHS) Method and associated IT Dashboard Server: Pathway Verification [ Time Frame: Through study completion, up to 10 months ]
    Evaluate the Mobile medical application software and associated IT server data processing pathways using % initial error rate (initial error rate and subsequent error rate, after any potential adjustments are made in mobile medical application if changes are required).
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

1. Age (18 years old or older)

2. Volunteers who provide written informed consent to participate in this study and who
are willing and able to perform frequent home spirometry monitoring and
laboratory-based spirometry, per protocol.

Exclusion Criteria:

1. Known cardiac, pulmonary or other condition, that may interfere with the subject's
ability to perform lab-based pulmonary function testing or standardized home
spirometry.

2. Any condition that would significantly affect the participant's ability to adhere to
the protocol, or affect interpretation of the study results.

3. Pregnant or planning to become pregnant during the study. Pregnant volunteers are
excluded as changes in spirometry associated with a gravid uterus could alter outcome
data. (Volunteers should take measures to prevent pregnancy while participating in the
study.)

4. Inability to provide informed consent or to comply with study assessments (e.g. due to
cognitive impairment or geographic distance or inadequate English
literacy/comprehension to operate the Home Spirometry System)

5. Concomitant participation in another trial with an investigational device or
investigational drug

6. Volunteers who have either a statistically significant (p-value <0.01) rate of change in FEV1 or a change in FEV1 rate of decline that exceeds an absolute value (+/-) of 30 mL/month using home spirometry based FEV1 values obtained during the normal range development period.

Contacts and Locations
Contacts

Contact: Kathy Dodds, RN 314-747-0497 doddsk@wustl.edu

Contact: George Despotis, MD gjdespotis@wustl.edu

Locations
Sponsors and Collaborators

Washington University School of Medicine

Mallinckrodt

Investigators

Principal Investigator: George Despotis, MD Washington University School of Medicine

More Information